Skip to main content

Table 5 Thromboembolic events in placebo-controlled studies for the prophylaxis of bleeding with rFVIIa in surgical interventions

From: Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data

Reference

Operation

Number of events/patients

Odds ratio (95% CI)

  

Placebo

rFVIIa

 

Levy et al. [51] (2006)

Dental operation

0/9

0/30

-

Raobaikady et al. [52] (2005)

Pelvic-acetabular surgery

0/24

0/24

-

Friederich et al. [3] (2003)

Prostatectomy

0/12

0/24

-

Lodge et al. [2] (2005)

Partial hepatectomy

3/68

6/132

0.97 (0.23–4.00)

Shao et al. [53] (2006)

Partial hepatectomy

1/81

3/151

0.62 (0.06–6.03)

Planinsic et al. [54] (2005)

Liver transplantation

3/19

8/64

1.53 (0.35–6.59)

Lodge et al. [55] (2005)

Liver transplantation

6/62

19/121

0.58 (0.22–1.52)

Diprose et al. [56] (2005)

Cardiopulmonary bypass

2/10

2/9

0.88 (0.10–7.95)

Sum

 

15/285

38/555

 

Weighted sum

 

5.97 (0.85–11.1)

6.42 (1.08–11.75)

0.806 (0.42–1.53)

  1. CI, confidence interval; rFVIIa, recombinant activated factor VII.